[Form 4] Heartflow, Inc. Insider Trading Activity
Bain Capital Life Sciences Investors, LLC and affiliated entities reported conversions of pre-IPO securities into Heartflow, Inc. common stock on 08/11/2025. The Issuer's Series F Preferred Stock converted on a 0.342466:1 basis into 12,014,234 common shares. A Subordinated Convertible Promissory Note with principal $6,595,648.51 converted into 433,924 common shares at a stated conversion price of $15.2. Following these transactions, the reporting group beneficially owned 12,448,158 common shares. The filings identify the reporting persons as directors and 10% owners and disclose an indirect ownership chain through several Bain Capital entities, with customary disclaimers about beneficial ownership.
Bain Capital Life Sciences Investors, LLC e società affiliate hanno comunicato la conversione di titoli pre-IPO in azioni ordinarie di Heartflow, Inc. il 08/11/2025. Le Series F Preferred Stock dell'Emittente sono state convertite in rapporto 0.342466:1 in 12,014,234 azioni ordinarie. Una Subordinated Convertible Promissory Note con capitale $6,595,648.51 è stata convertita in 433,924 azioni ordinarie al prezzo di conversione dichiarato di $15.2. A seguito di tali operazioni, il gruppo segnalante deteneva beneficiariamente 12,448,158 azioni ordinarie. Le dichiarazioni identificano le persone segnalanti come amministratori e detentori del 10% e rivelano una catena di proprietà indiretta attraverso diverse entità di Bain Capital, con i consueti disclaimer sulla titolarità beneficiaria.
Bain Capital Life Sciences Investors, LLC y entidades afiliadas informaron conversiones de valores pre-IPO en acciones ordinarias de Heartflow, Inc. el 08/11/2025. Las Series F Preferred Stock del emisor se convirtieron a una relación de 0.342466:1 en 12,014,234 acciones ordinarias. Una Subordinated Convertible Promissory Note con principal de $6,595,648.51 se convirtió en 433,924 acciones ordinarias a un precio de conversión declarado de $15.2. Tras estas operaciones, el grupo informante poseía beneficiariamente 12,448,158 acciones ordinarias. Las presentaciones identifican a las personas informantes como directores y propietarios del 10% y revelan una cadena de propiedad indirecta a través de varias entidades de Bain Capital, con los descargos habituales sobre la propiedad beneficiaria.
Bain Capital Life Sciences Investors, LLC 및 계열사는 08/11/2025에 Heartflow, Inc. 보통주로의 사전상장(pre-IPO) 증권 전환을 보고했습니다. 발행인의 Series F Preferred Stock는 0.342466:1 비율로 전환되어 12,014,234 보통주가 되었습니다. 원금 $6,595,648.51의 Subordinated Convertible Promissory Note는 명시된 전환가격 $15.2에 따라 433,924 보통주로 전환되었습니다. 이러한 거래 이후 보고 그룹은 실질적으로 12,448,158 보통주를 보유하게 되었습니다. 제출서류는 보고자를 이사 및 10% 보유자로 식별하고 있으며, 여러 Bain Capital 계열사를 통한 간접 소유구조를 공개하고 통상적인 실소유권 관련 면책조항을 포함하고 있습니다.
Bain Capital Life Sciences Investors, LLC et des entités affiliées ont déclaré, le 08/11/2025, la conversion de titres pré-IPO en actions ordinaires de Heartflow, Inc. Les Series F Preferred Stock de l'émetteur ont été converties au ratio 0,342466:1 en 12,014,234 actions ordinaires. Un Subordinated Convertible Promissory Note d'un principal de $6,595,648.51 a été converti en 433,924 actions ordinaires à un prix de conversion déclaré de $15.2. À la suite de ces opérations, le groupe déclarante détenait à titre bénéficiaire 12,448,158 actions ordinaires. Les dépôts identifient les personnes déclarante comme administrateurs et détenteurs de 10 % et révèlent une chaîne de propriété indirecte via plusieurs entités de Bain Capital, avec les mentions habituelles concernant la propriété bénéficiaire.
Bain Capital Life Sciences Investors, LLC und verbundene Unternehmen meldeten am 08/11/2025 die Umwandlung von Pre-IPO-Wertpapieren in Stammaktien der Heartflow, Inc. Die Series F Preferred Stock des Emittenten wurden im Verhältnis 0,342466:1 in 12,014,234 Stammaktien umgewandelt. Eine Subordinated Convertible Promissory Note mit einem Kapitalbetrag von $6,595,648.51 wurde zu einem festgelegten Umwandlungspreis von $15.2 in 433,924 Stammaktien getauscht. Nach diesen Transaktionen hielt die meldende Gruppe wirtschaftlich 12,448,158 Stammaktien. Die Unterlagen nennen die meldenden Personen als Direktoren und 10%-Eigentümer und offenbaren eine indirekte Eigentumskette über mehrere Bain Capital-Einheiten, mit den üblichen Haftungsausschlüssen zur wirtschaftlichen Eigentümerschaft.
- Automatic conversion of Series F preferred into 12,014,234 common shares completed on 08/11/2025
- Subordinated note converted into 433,924 common shares at a stated price of $15.2
- Total beneficial ownership reported as 12,448,158 common shares, demonstrating a significant insider stake
- Indirect ownership through multiple Bain Capital entities may make exact voting and dispositive control less transparent
- Disclaimers in the filing state each entity disclaims beneficial ownership except to the extent of pecuniary interest
Insights
TL;DR: Insider conversions on 08/11/2025 resulted in 12.45M common shares held indirectly by Bain Capital entities.
The Form 4 documents routine post-IPO corporate conversions: 35,081,564 Series F preferred shares converted into 12,014,234 common shares and a subordinated convertible note converted into 433,924 common shares at a stated conversion price of $15.2. The reporting group holds 12,448,158 common shares following conversion. These are recorded as indirect holdings through a multi-entity Bain Capital structure, with each entity disclaiming direct beneficial ownership except to the extent of pecuniary interest. The disclosure is procedural and clarifies ownership but does not by itself indicate a change in voting control beyond the reported indirect holdings.
TL;DR: The filing documents conversion mechanics and an indirect ownership chain; disclosures and disclaimers are standard.
The footnotes explain that Series F preferred shares automatically converted immediately prior to the IPO and that the outstanding subordinated note converted at 80% of the IPO price (reflected here as $15.2). The filing lists Bain Capital Life Sciences Investors, LLC and affiliated entities as reporting persons, each potentially sharing voting and dispositive power over the disclosed shares, while also disclaiming beneficial ownership beyond pecuniary interest. From a governance perspective, the form provides required transparency about insider positions and related-party ownership structure.
Bain Capital Life Sciences Investors, LLC e società affiliate hanno comunicato la conversione di titoli pre-IPO in azioni ordinarie di Heartflow, Inc. il 08/11/2025. Le Series F Preferred Stock dell'Emittente sono state convertite in rapporto 0.342466:1 in 12,014,234 azioni ordinarie. Una Subordinated Convertible Promissory Note con capitale $6,595,648.51 è stata convertita in 433,924 azioni ordinarie al prezzo di conversione dichiarato di $15.2. A seguito di tali operazioni, il gruppo segnalante deteneva beneficiariamente 12,448,158 azioni ordinarie. Le dichiarazioni identificano le persone segnalanti come amministratori e detentori del 10% e rivelano una catena di proprietà indiretta attraverso diverse entità di Bain Capital, con i consueti disclaimer sulla titolarità beneficiaria.
Bain Capital Life Sciences Investors, LLC y entidades afiliadas informaron conversiones de valores pre-IPO en acciones ordinarias de Heartflow, Inc. el 08/11/2025. Las Series F Preferred Stock del emisor se convirtieron a una relación de 0.342466:1 en 12,014,234 acciones ordinarias. Una Subordinated Convertible Promissory Note con principal de $6,595,648.51 se convirtió en 433,924 acciones ordinarias a un precio de conversión declarado de $15.2. Tras estas operaciones, el grupo informante poseía beneficiariamente 12,448,158 acciones ordinarias. Las presentaciones identifican a las personas informantes como directores y propietarios del 10% y revelan una cadena de propiedad indirecta a través de varias entidades de Bain Capital, con los descargos habituales sobre la propiedad beneficiaria.
Bain Capital Life Sciences Investors, LLC 및 계열사는 08/11/2025에 Heartflow, Inc. 보통주로의 사전상장(pre-IPO) 증권 전환을 보고했습니다. 발행인의 Series F Preferred Stock는 0.342466:1 비율로 전환되어 12,014,234 보통주가 되었습니다. 원금 $6,595,648.51의 Subordinated Convertible Promissory Note는 명시된 전환가격 $15.2에 따라 433,924 보통주로 전환되었습니다. 이러한 거래 이후 보고 그룹은 실질적으로 12,448,158 보통주를 보유하게 되었습니다. 제출서류는 보고자를 이사 및 10% 보유자로 식별하고 있으며, 여러 Bain Capital 계열사를 통한 간접 소유구조를 공개하고 통상적인 실소유권 관련 면책조항을 포함하고 있습니다.
Bain Capital Life Sciences Investors, LLC et des entités affiliées ont déclaré, le 08/11/2025, la conversion de titres pré-IPO en actions ordinaires de Heartflow, Inc. Les Series F Preferred Stock de l'émetteur ont été converties au ratio 0,342466:1 en 12,014,234 actions ordinaires. Un Subordinated Convertible Promissory Note d'un principal de $6,595,648.51 a été converti en 433,924 actions ordinaires à un prix de conversion déclaré de $15.2. À la suite de ces opérations, le groupe déclarante détenait à titre bénéficiaire 12,448,158 actions ordinaires. Les dépôts identifient les personnes déclarante comme administrateurs et détenteurs de 10 % et révèlent une chaîne de propriété indirecte via plusieurs entités de Bain Capital, avec les mentions habituelles concernant la propriété bénéficiaire.
Bain Capital Life Sciences Investors, LLC und verbundene Unternehmen meldeten am 08/11/2025 die Umwandlung von Pre-IPO-Wertpapieren in Stammaktien der Heartflow, Inc. Die Series F Preferred Stock des Emittenten wurden im Verhältnis 0,342466:1 in 12,014,234 Stammaktien umgewandelt. Eine Subordinated Convertible Promissory Note mit einem Kapitalbetrag von $6,595,648.51 wurde zu einem festgelegten Umwandlungspreis von $15.2 in 433,924 Stammaktien getauscht. Nach diesen Transaktionen hielt die meldende Gruppe wirtschaftlich 12,448,158 Stammaktien. Die Unterlagen nennen die meldenden Personen als Direktoren und 10%-Eigentümer und offenbaren eine indirekte Eigentumskette über mehrere Bain Capital-Einheiten, mit den üblichen Haftungsausschlüssen zur wirtschaftlichen Eigentümerschaft.
FAQ
Who filed the Form 4 reporting insider activity for Heartflow (HTFL)?
What transactions were reported for HTFL on 08/11/2025?
How many common shares did Bain Capital beneficially own after the reported transactions?
How many common shares resulted from the Series F preferred conversion?
What were the terms of the promissory note conversion?
What is the reporting persons' relationship to Heartflow?
